QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
Log in

OTCMKTS:CNVVYCONVATEC GRP PL/ADR Stock Price, Forecast & News

$10.06
-0.14 (-1.37 %)
(As of 08/11/2020 04:00 PM ET)
Add
Compare
Today's Range
$10.06
Now: $10.06
$10.06
50-Day Range
$9.46
MA: $10.12
$10.75
52-Week Range
$6.69
Now: $10.06
$11.28
Volume2,500 shs
Average Volume2,410 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide. It offers advanced wound dressings and skin care products for the management of chronic wounds resulting from various conditions, such as diabetes, immobility, and venous disease, as well as for traumatic injury, burns, invasive surgery, and other causes. The company also provides devices, accessories, and services for people with an ostomy or stoma resulting from colorectal cancer, inflammatory bowel disease, bladder cancer, obesity, and other causes. In addition, it offers continence and critical care products, including intermittent urinary catheters; and products for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida, and urological disorders, as well as devices and products use in intensive care units and hospital settings. Further, the company provides advanced systems for managing acute fecal incontinence, as well as for monitoring urine production output and intra-abdominal pressure; and various disposable medical devices, such as wound drainage systems, urine collection bags and catheters, airway management and oxygen/aerosol therapy devices, suction handles and tubes, gastroenterology tubes, and securement devices. Additionally, it offers disposable infusion sets to the manufacturers of insulin pumps for diabetes, as well as similar pumps that are used in continuous infusion treatments for other conditions; and various products to hospitals and the home healthcare sector. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. The company was founded in 2008 and is headquartered in Reading, the United Kingdom.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 1.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.36 out of 5 stars


Industry, Sector and Symbol

Industry Medical Instruments & Supplies
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:CNVVY
CUSIPN/A
CIKN/A
Phone441189528100

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees9,413
Next Earnings DateN/A
OptionableNot Optionable
$10.06
-0.14 (-1.37 %)
(As of 08/11/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CNVVY News and Ratings via Email

Sign-up to receive the latest news and ratings for CNVVY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











CONVATEC GRP PL/ADR (OTCMKTS:CNVVY) Frequently Asked Questions

How has CONVATEC GRP PL/ADR's stock been impacted by COVID-19 (Coronavirus)?

CONVATEC GRP PL/ADR's stock was trading at $8.86 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CNVVY shares have increased by 13.5% and is now trading at $10.06.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of CONVATEC GRP PL/ADR?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CONVATEC GRP PL/ADR in the last year. There are currently 3 sell ratings, 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for CONVATEC GRP PL/ADR
.

Has CONVATEC GRP PL/ADR been receiving favorable news coverage?

News headlines about CNVVY stock have been trending neutral recently, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. CONVATEC GRP PL/ADR earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future.
View the latest news about CONVATEC GRP PL/ADR
.

Are investors shorting CONVATEC GRP PL/ADR?

CONVATEC GRP PL/ADR saw a decline in short interest in the month of February. As of February 15th, there was short interest totaling 100 shares, a decline of 95.0% from the January 31st total of 2,000 shares. Based on an average daily trading volume, of 5,300 shares, the short-interest ratio is presently 0.0 days.
View CONVATEC GRP PL/ADR's Short Interest
.

Who are some of CONVATEC GRP PL/ADR's key competitors?

Who are CONVATEC GRP PL/ADR's key executives?

CONVATEC GRP PL/ADR's management team includes the following people:
  • Mr. Rick D. Anderson, Interim CEO & Non-Exec. Director (Age 58)
  • Mr. Frank M. Schulkes, CFO & Director (Age 57)
  • Mr. John Crosse, VP of Investor Relations
  • Mr. Adam B. Deutsch, Exec. VP of Corp. Devel. & Gen. Counsel
  • Mr. Douglas Le Fort, Sr. VP of Corp. Devel. (Age 53)

What is CONVATEC GRP PL/ADR's stock symbol?

CONVATEC GRP PL/ADR trades on the OTCMKTS under the ticker symbol "CNVVY."

How do I buy shares of CONVATEC GRP PL/ADR?

Shares of CNVVY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is CONVATEC GRP PL/ADR's stock price today?

One share of CNVVY stock can currently be purchased for approximately $10.06.

What is CONVATEC GRP PL/ADR's official website?

The official website for CONVATEC GRP PL/ADR is www.convatecgroup.com.

How can I contact CONVATEC GRP PL/ADR?

The company can be reached via phone at 441189528100.

This page was last updated on 8/11/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.